|
Collaboration Agreement - Additional Information (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2013
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2013
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2012
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2011
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Dec. 31, 2013
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Minimum [Member]
|
Dec. 31, 2013
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Maximum [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
|
Dec. 31, 2013
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | |||||||||||||||||||||
| Maximum amount receivable | 370,000,000 | 370,000,000 | ||||||||||||||||||||
| Equity investment | 53,777,000 | 10,000,000 | ||||||||||||||||||||
| Royalties at percentage rates ranging | Mid-teens to mid-twenties on net sales | |||||||||||||||||||||
| Share premium | 20.00% | |||||||||||||||||||||
| Common shares, purchase price | $ 37.38 | |||||||||||||||||||||
| Common shares purchased | 267,531 | |||||||||||||||||||||
| Average premium period | 30 days | |||||||||||||||||||||
| Research and development | 13,195,000 | 18,004,000 | 13,263,000 | 10,855,000 | 15,645,000 | 12,895,000 | 6,326,000 | 5,082,000 | 55,317,000 | 39,948,000 | 21,553,000 | 10,000,000 | 300,000 | |||||||||
| Percentage of milestone payments required to be paid to third party | 31.00% | |||||||||||||||||||||
| Percentage of net sales required to be paid as royalty to third party | 4.88% | 8.00% | ||||||||||||||||||||
| Direct and indirect costs incurred | 30,000,000 | |||||||||||||||||||||
| Required period of notice for termination of Collaboration agreement | 3 months | 6 months | ||||||||||||||||||||
| Expiration of royalties | 10 years | |||||||||||||||||||||
| Period of authorization change | 90 days | |||||||||||||||||||||
| Revenue | 8,604,000 | 9,862,000 | 6,340,000 | 5,076,000 | 9,780,000 | 6,570,000 | 2,429,000 | 1,316,000 | 29,882,000 | 20,095,000 | 5,496,000 | 29,900,000 | 20,100,000 | 5,500,000 | ||||||||
| Receivable for unbilled expense reimbursements | 8,600,000 | |||||||||||||||||||||
| Amounts receivable | 8,657,000 | 714,000 | 8,657,000 | 714,000 | ||||||||||||||||||
| Milestone payment due | 20,000,000 | 20,000,000 | ||||||||||||||||||||
| Period of milestone payment | 21 days | 21 days | ||||||||||||||||||||
| Reserve for contingency of non payment of non-royalty milestone amount | 20,000,000 | 20,000,000 | ||||||||||||||||||||
| Milestone payment made | 10,000,000 | 10,000,000 | ||||||||||||||||||||
| Balance amount of milestone payment | 10,000,000 | 10,000,000 | ||||||||||||||||||||
| Balance in advanced reimbursement of development activities | $ 30,000,000 | |||||||||||||||||||||